[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-morbid\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-morbid":26},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,74,0,25,[9,46,61,76,91,106,131,160,185,202,217,232,247,262,277,292,307,324,339,354,369,401,434,459,488],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100327083","bariatric-surgery-and-pharmacokinetics-of-paracetamol-100327083",false,"NCT03538457","Bariatric Surgery and Pharmacokinetics of Paracetamol","Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol","Inclusion Criteria:\n\n* Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway\n* Being a Norwegian citizen\n\nExclusion Criteria:\n\n* Having previously undergone resections in the GI-tract","ALL","18 Years","70 Years",{"count":21,"type":22},12,"ESTIMATED","OBSERVATIONAL","Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on paracetamol are investigated.",[26],"Obesity, Morbid",[28,29,30,31,32],"Bariatric surgery","Gastrointestinal tract","Biological availability","Pharmacokinetics","Acetaminophen","RECRUITING","2026-08-12",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":37},"2016-11-02",{"date":41,"type":22},"2026-10",{"name":43,"class":44},"Norwegian University of Science and Technology","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":45},"100326846","bariatric-surgery-and-pharmacokinetics-of-valsartan-100326846","NCT03535376","Bariatric Surgery and Pharmacokinetics of Valsartan","Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on valsartan are investigated.",[26],[28,29,30,31,56],"Valsartan",{"date":36,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":72,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":75,"locationsCount":45},"100325660","bariatric-surgery-and-pharmacokinetics-of-metoprolol-100325660","NCT03519906","Bariatric Surgery and Pharmacokinetics of Metoprolol","Bariatric Surgery and Pharmacokinetics of Metoprolol: BAR-MEDS Metoprolol",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on metoprolol are investigated.",[26],[28,29,30,31,71],"Metoprolol",{"date":36,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":90,"locationsCount":45},"100325659","bariatric-surgery-and-pharmacokinetics-of-losartan-100325659","NCT03519893","Bariatric Surgery and Pharmacokinetics of Losartan","Bariatric Surgery and Pharmacokinetics of Losartan: BAR-MEDS Losartan",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on losartan are investigated.",[26],[28,29,30,31,86],"Losartan",{"date":36,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":98,"conditions":99,"keywords":100,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":102,"startDateStruct":103,"completionDateStruct":104,"leadSponsor":105,"locationsCount":45},"100323913","bariatric-surgery-and-pharmacokinetics-of-lamotrigine-100323913","NCT03497143","Bariatric Surgery and Pharmacokinetics of Lamotrigine","Bariatric Surgery and Pharmacokinetics Lamotrigine: BAR-MEDS Lamotrigine",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on lamotrigine are investigated.",[26],[28,29,30,31,101],"Lamotrigine",{"date":36,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100509833","postextubation-use-of-noninvasive-respiratory-support-in-severely-obese-patients-100509833","NCT05918575","Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","A Randomized Controlled Trial of Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients","Inclusion Criteria:\n\n1. Adult, age ≥ 18 years old\n2. Receiving invasive mechanical ventilation for ≥24 hours\n3. BMI ≥40 kg\u002Fm2\n4. Undergoing planned extubation per treating team\n5. Arterial pH ≥7.35 or venous pH ≥ 7.31 within 30 mins of spontaneous breathing trial (SBT)\n\nExclusion Criteria:\n\n1. Pregnant\n2. Use of extra-corporeal membrane oxygenation\n3. Chronic tracheostomy in place\n4. Unplanned or accidental extubation\n5. Terminal\u002Fcompassionate extubation\n6. Contraindication to NIV use\n7. Intubated because of an acute exacerbation of COPD\n8. Underlying neuromuscular disease\n9. No reintubation requested by patient\u002Ffamily\n10. Documented\u002Fknown history of chronic hypercapnic respiratory failure on home NIV (including bilevel PAP).\n11. Enrolled in any other outcome study\n12. Treating clinician feels that HFNC or NIV are either mandatory or contraindicated for a given patient",{"count":114,"type":22},250,"INTERVENTIONAL",[117],"NA","Around 20% of the obese patients with higher body mass index (BMI) who are taken off the breathing tube and breathing machine (ventilator) end up needing it back to support breathing. The re-application of breathing tube is associated with poor outcomes, including high risk of pneumonia, longer hospital stays, and death. The purpose of this study is to assess if prophylactic use of noninvasive breathing support after removing the breathing tube lowers the chance of needing the breathing tube again.",[26,120],"Extubation Failure","2026-08-04",{"date":123,"type":37},"2026-08-07",{"date":125,"type":37},"2023-07-10",{"date":127,"type":22},"2028-12-01",{"name":129,"class":44},"Rush University Medical Center",5,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":4},"100649555","impact-of-mbs-on-body-composition-basal-metabolic-rates-and-muscle-functions-in-morbid-obese-patients-100649555","NCT07737860","Impact of MBS on Body Composition, Basal Metabolic Rates and Muscle Functions in Morbid Obese Patients","Impact of Bariatric Surgery on Body Composition, Basal Metabolic Rates and Muscle Functions in Morbid Obese Patients: A Prospective Observational Study","BARCOM","Inclusion Criteria:\n\n* BMI \\> 35 with or without obesity-related comorbidities Planned for Bariatric and Metabolic Surgery\n\nExclusion Criteria:\n\n* Known endocrine disorders (Cushing's and Untreated hypothyroidism)\n* History of prior bariatric surgery\n* Inability to comply with follow-up scheduleLost to follow-up before 3 months post-treatment","60 Years",{"count":141,"type":22},21,"PRIMARY OBJECTIVE To evaluate the changes in body composition in morbid obese patients following bariatric and metabolic surgery\n\nSecondary Objectives:\n\n1. To assess changes in BMR in obese patients following bariatric surgery\n2. To evaluate muscles strength and muscle performance parameters in obese patients following bariatric surgery\n3. To assess change in inflammatory and metabolic parameters following bariatric surgery In this study, morbidly obese patients undergoing bariatric surgery will be assessed at baseline and followed by 3rd and 6 months to evaluate various physiological and biochemical changes. Anthropometric measurements including height, weight, BMI, and waist-hip ratio will be recorded. Body composition will be assessed using Bioelectrical Impedance Analysis (BIA), which will provide data on percentage body fat (PBF), segmental muscle mass (SMM), segmental fat mass (SFM), and skeletal muscle index (SMI). Basal metabolic rate (BMR) will also be measured through BIA. Muscle strength will be evaluated using a hand grip dynamometer, while muscle performance will be assessed via gait speed using the 6-meter walk test. Inflammatory markers such as high-sensitivity C-reactive protein (HsCRP), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6) will be analyzed. Additionally, metabolic parameters including thyroid-stimulating hormone (TSH), fasting and postprandial blood glucose, HbA1c, and lipid profile will be measured to understand the systemic effects of the surgery.",[26,144,145],"Obesity; Endocrine","Fat Disorder",[147,148,149],"BMR","Fat composition","Muscle strength","NOT_YET_RECRUITING","2026-07-29",{"date":153,"type":37},"2026-07-30",{"date":155,"type":22},"2026-09-01",{"date":157,"type":22},"2027-12",{"name":159,"class":44},"All India Institute of Medical Sciences, Bhubaneswar",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":181,"leadSponsor":183,"locationsCount":45},"100647215","investigating-metabolic-brain-and-cognitive-alterations-through-bariatric-surgery-100647215","NCT07704229","Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric Surgery","Investigating Metabolic, Brain, and Cognitive Alterations Through Bariatric Surgery: Key Determinants and Prospective Outcomes","BRAINS","Inclusion Criteria:\n\n* Women or men between 18 and 65 years who meet the Guidelines for bariatric surgery (BM I≥ 30 kg\u002Fm2 with major comorbidities or BMI ≥ 35 kg\u002Fm2\n\nExclusion Criteria:\n\n* Pregnancy\n* Liver cirrhosis\n* Unstable medical, surgical or psychiatric conditions\n* Substance or alcohol abuse\n* Medications affecting the central nervous system\n* Previous gastric, oesophageal, brain, or bariatric surgeries\n* Gastrointestinal inflammatory diseases or ulcers\n* MRI contraindications","65 Years",{"count":170,"type":22},150,"Despite global efforts, the prevalence of obesity continues to rise, with rates in Canada tripling over the past three decades. In addition to the well-established risk of cardiometabolic conditions such as heart disease and diabetes, obesity has been associated with cognitive decline and an increased risk of dementia later in life. Sleeve gastrectomy, the most widely used surgical treatment for severe obesity, has proven effective in promoting significant weight loss and improving overall health. Emerging research, including our recent brain imaging study, suggests that this surgery may also have a positive impact on brain health. Our findings demonstrated significant improvements, with patients experiencing reductions in brain age by 2.9 and 5.6 years 12 and 24 months post-surgery, respectively. Despite these promising results, the long-term effects of sleeve gastrectomy on brain health and cognitive function remains poorly understood. While some patients experience cognitive improvements following surgery, others do not, and the factors driving this variability remain unknown.\n\nThis proposal aims to comprehensively investigate the impact of bariatric surgery on brain health by examining its cognitive consequences, determinants, and drivers. Understanding the key factors that contribute to brain health improvements after bariatric surgery is essential for optimizing its benefits, preventing relapse and developing personalized interventions to maintain or enhance brain health in individuals living with obesity.",[26],[174,175,176],"bariatric surgery","Brain","Magnetic Resonance Imaging","2026-07-15",{"date":179,"type":37},"2026-07-16",{"date":155,"type":22},{"date":182,"type":22},"2031-03-31",{"name":184,"class":44},"Laval University",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":192,"conditions":193,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":200,"leadSponsor":201,"locationsCount":45},"100323914","bariatric-surgery-and-pharmacokinetics-of-lercanidipine-100323914","NCT03497156","Bariatric Surgery and Pharmacokinetics of Lercanidipine","Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on lercanidipine are investigated.",[26],[28,29,30,31,195],"Lercanidipine","2026-07-06",{"date":198,"type":37},"2026-07-08",{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":209,"conditions":210,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":216,"locationsCount":45},"100322338","bariatric-surgery-and-pharmacokinetics-of-irbesartan-100322338","NCT03476603","Bariatric Surgery and Pharmacokinetics of Irbesartan","Bariatric Surgery and Pharmacokinetics Irbesartan: BAR-MEDS Irbesartan",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on irbesartan are investigated.",[26],[28,29,30,31,212],"Irbesartan",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":224,"conditions":225,"keywords":226,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":230,"leadSponsor":231,"locationsCount":45},"100322336","bariatric-surgery-and-pharmacokinetics-of-ibuprofen-100322336","NCT03476577","Bariatric Surgery and Pharmacokinetics of Ibuprofen","Bariatric Surgery and Pharmacokinetics Ibuprofen: BAR-MEDS Ibuprofen",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on ibuprofen are investigated.",[26],[28,29,30,31,227],"Ibuprofen",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":239,"conditions":240,"keywords":241,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":246,"locationsCount":45},"100322334","bariatric-surgery-and-pharmacokinetics-of-hydrochlorothiazide-100322334","NCT03476551","Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","Bariatric Surgery and Pharmacokinetics Hydrochlorothiazide: BAR-MEDS Hydrochlorothiazide",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on hydrochlorothiazide are investigated.",[26],[28,29,30,31,242],"Hydrochlorothiazide",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":254,"conditions":255,"keywords":256,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":261,"locationsCount":45},"100322333","bariatric-surgery-and-pharmacokinetics-of-gabapentin-100322333","NCT03476538","Bariatric Surgery and Pharmacokinetics of Gabapentin","Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.",[26],[28,29,30,31,257],"Gabapentin",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":269,"conditions":270,"keywords":271,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":273,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":276,"locationsCount":45},"100322332","bariatric-surgery-and-pharmacokinetics-of-fluoxetine-100322332","NCT03476525","Bariatric Surgery and Pharmacokinetics of Fluoxetine","Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on fluoxetine are investigated.",[26],[28,29,30,31,272],"Fluoxetine",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":291,"locationsCount":45},"100321094","bariatric-surgery-and-pharmacokinetics-of-enalapril-100321094","NCT03460366","Bariatric Surgery and Pharmacokinetics of Enalapril","Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on enalapril are investigated.",[26],[28,29,30,31,287],"Enalapril",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":305,"leadSponsor":306,"locationsCount":45},"100321091","bariatric-surgery-and-pharmacokinetics-of-candesartan-100321091","NCT03460327","Bariatric Surgery and Pharmacokinetics of Candesartan","Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.",[26],[28,29,30,31,302],"Candesartan",{"date":198,"type":37},{"date":39,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":314,"conditions":315,"keywords":316,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100320259","bariatric-surgery-and-pharmacokinetics-of-chlorprothixene-100320259","NCT03449485","Bariatric Surgery and Pharmacokinetics of Chlorprothixene","Bariatric Surgery and Pharmacokinetics of Chlorprothixene: BAR-MEDS Chlorprothixene",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on chlorprothixene.",[26],[28,29,30,31,317],"Chlorprothixene",{"date":198,"type":37},{"date":320,"type":37},"2018-01-02",{"date":322,"type":22},"2026-12",{"name":43,"class":44},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":331,"conditions":332,"keywords":333,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":337,"leadSponsor":338,"locationsCount":45},"100320258","bariatric-surgery-and-pharmacokinetics-of-quetiapine-100320258","NCT03449472","Bariatric Surgery and Pharmacokinetics of Quetiapine","Bariatric Surgery and Pharmacokinetics Quetiapine: BAR-MEDS Quetiapine",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on quetiapine are investigated.",[26],[28,29,30,31,334],"Quetiapine fumarate",{"date":198,"type":37},{"date":320,"type":37},{"date":41,"type":22},{"name":43,"class":44},{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":346,"conditions":347,"keywords":348,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":352,"leadSponsor":353,"locationsCount":45},"100320205","bariatric-surgery-and-pharmacokinetics-of-apixaban-100320205","NCT03448783","Bariatric Surgery and Pharmacokinetics of Apixaban","Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on apixaban.",[26],[28,29,30,31,349],"Apixaban",{"date":198,"type":37},{"date":320,"type":37},{"date":322,"type":22},{"name":43,"class":44},{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":360,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":361,"conditions":362,"keywords":363,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":368,"locationsCount":45},"100319547","bariatric-surgery-and-pharmacokinetics-of-ramipril-100319547","NCT03440177","Bariatric Surgery and Pharmacokinetics of Ramipril","Bariatric Surgery and Pharmacokinetics of Ramipril: BAR-MEDS Ramipril",{"count":21,"type":22},"Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study we investigate the pharmacokinetic effects of bariatric surgery on ramipril.",[26],[28,29,30,31,364],"Ramipril",{"date":198,"type":37},{"date":320,"type":37},{"date":322,"type":22},{"name":43,"class":44},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":375,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":377,"enrollmentInfo":378,"targetDuration":4,"studyType":115,"phases":380,"briefSummary":381,"conditions":382,"keywords":387,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":45},"100531527","trans-nasal-endoscopy-for-bariatric-patients-100531527","NCT06200961","Trans-nasal Endoscopy for Bariatric Patients","Use of Sedation-Free Transnasal Endoscopy to Improve Access and Lower Costs of Endoscopic Evaluations in a Bariatric Medical and Surgical Program","TNE","Inclusion Criteria:\n\n1. Patient 18 years of age and less than 90 years of age with clinically referred for esophagoscopy, gastroscopy, or esophagogastroduodenoscopy (EGD)\n2. Cared for in metabolic and bariatric clinic\n\nExclusion Criteria:\n\n1. Patient \\\u003C18 years of age\n2. Medically contraindicated to perform EGD or TNE\n3. Inability to provide informed consent","90 Years",{"count":379,"type":22},100,[117],"This study plans to learn if the EvoEndo Endoscopy system can be used to evaluate, provide and follow up care for upper gastrointestinal tract diseases in the bariatric population. The smallest current scope available for such a technique is an adult transnasal endoscope with a larger diameter, a pulmonary bronchoscope or Ear Nose and Throat (ENT) laryngoscope. This study is evaluating a newly Food and Drug Administration (FDA) cleared ultra-slim, single-use, endoscope specifically designed for transnasal endoscopy to evaluate its use in adult upper tract gastrointestinal diseases. If such a technique is successful it could improve the safety, cost, and access of endoscopic care for patients in need of an endoscopic evaluation for a bariatric medical condition.",[383,26,384,385,386],"Obesity","Obese","GI Disorders","Gastrointestinal Diseases",[388,389,390,391],"Transnasal Endoscopy (TNE)","Esophagogastroduodenoscopy (EGD)","Upper Endoscopy","Endoscopy","2026-06-23",{"date":394,"type":37},"2026-06-25",{"date":396,"type":37},"2026-04-20",{"date":398,"type":22},"2028-06",{"name":400,"class":44},"Christopher C. Thompson, MD, MSc",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":405,"acronym":406,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":408,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":115,"phases":411,"briefSummary":412,"conditions":413,"keywords":415,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":45},"100232937","obesity-cohort--medical-follow-up-of-severe-or-morbid-obese-patients-undergoing-bariatric-surgery-100232937","NCT02310178","Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery","BAREVAL","Inclusion Criteria:\n\n* Only be considered in patients operated and followed at CHU Montpellier with bariatric surgery\n* Patients treated by bariatric surgery on CHU Montpellier\n* Agreed to participate to the study by signing an informed consent\n* Eligible to health insurance\n\nExclusion Criteria:\n\n* Unable to follow the patient in the long term (foreign patients, surgical use ...)\n* Inability to follow in the long run","15 Years",{"count":410,"type":22},750,[117],"The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.",[26,414],"Bariatric Surgery Candidate",[416,417,418,419,420,421,422,423,424],"weight loss","sleeve gastrectomy","gastric bypass","gastric banding","bariatric procedures","cohort","morbid obesity","medical and economical impact","severe obesity","2026-06-17",{"date":427,"type":37},"2026-06-22",{"date":429,"type":37},"2012-05-21",{"date":431,"type":22},"2028-12",{"name":433,"class":44},"University Hospital, Montpellier",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":442,"targetDuration":4,"studyType":115,"phases":444,"briefSummary":445,"conditions":446,"keywords":447,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":45},"100602125","low-impact-laparoscopy-in-bariatric-surgery-100602125","NCT07119437","Low Impact Laparoscopy In Bariatric Surgery","Low Impact Laparoscopy In Bariatric Surgery- A Monocentric Randomised Trial Comparing Low-Pressure Pneumoperitoneum Plus Microsurgery Versus Standard Laparoscopy","LILYBET","Inclusion Criteria:\n\n* Age between 18 years-old and 65 years-old\n* BMI (Body Mass Index) \\>35 Kg\u002Fm2 and \\\u003C 45 Kg\u002Fm2;\n* Patients candidate to sleeve gastrectomy\n\nExclusion Criteria:\n\n* Patients with neurological and\u002For psychiatric disorders\n* Patients with Chronic Pain Syndrome\n* Patients with a history of surgical procedures using a laparotomic approach in the upper abdominal quadrants",{"count":443,"type":22},128,[117],"The goal of this clinical trial is to learn if low pressure pneumoperitoneum and small incisions (low impact laparoscopy, LIL) works to reduce pain and improve pulmonary function in patients underwent to bariatric surgery.\n\nIt will also learn about the safety and patients' satisfaction of the procedure. The main questions it aims to answer are:\n\nDoes LIL lower post surgical pain and improve pulmonary function? Is LIL safe for obese patients? Researchers will compare LIL to standard laparoscopy performing sleeve gastrectomy in patients with obesity.\n\nParticipants will:\n\nbe randomised to LIL group or standard laparoscopy. After the operation the researchers will evaluate the pain and the efficiency of lung ventilation at pre-established intervals. after 3 months the patients will complete a questionnaire on aesthetic satisfaction and overall satisfaction.",[26],[448,449,417],"obesity","low impact laparoscopy","2026-06-16",{"date":452,"type":37},"2026-06-18",{"date":454,"type":37},"2025-02-04",{"date":456,"type":22},"2026-10-04",{"name":458,"class":44},"Fondazione Policlinico Universitario Campus Bio-Medico",{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":115,"phases":468,"briefSummary":469,"conditions":470,"keywords":477,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":45},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244","NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women",{"count":467,"type":22},165,[117],"This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[26,471,472,473,474,475,476],"Obesity and Overweight","Bariatric Surgery","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[478,464],"GEROM73","2026-06-09",{"date":481,"type":37},"2026-06-10",{"date":483,"type":37},"2025-06-17",{"date":485,"type":22},"2030-09-09",{"name":487,"class":44},"Centre Hospitalier Metropole Savoie",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":17,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":500,"conditions":501,"keywords":505,"overallStatus":150,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":45},"100643167","evaluation-of-metabolic-parameters-intestinal-permeability-and-gastrointestinal-symptoms-after-bariatric-surgery-in-body-weight-management-100643167","NCT07643376","Evaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management","Evaluation of Postoperative Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms in Body Weight Management After Laparoscopic Sleeve Gastrectomy","METABAR","Inclusion Criteria:\n\n* Underwent Laparoscopic Sleeve Gastrectomy (LSG) within the last 1 month\n* Aged between 19-50 years\n* BMI ≥40 kg\u002Fm² or BMI ≥35 kg\u002Fm² with obesity-related comorbidities\n* Signed informed consent form\n* Non-smoker and non-alcohol dependent\n\nExclusion Criteria:\n\n* Did not undergo or is not planned to undergo LSG\n* Outside the age range of 19-50 years\n* Did not sign the informed consent form\n* BMI \\\u003C40 kg\u002Fm² or BMI \\\u003C35 kg\u002Fm² without obesity-related comorbidities\n* Smoker or alcohol dependent\n* Has an inflammatory disease\n* Currently using probiotics, antibiotics, or fiber supplements\n* Has a psychiatric disorder","19 Years","50 Years",{"count":499,"type":22},40,"This study aims to evaluate the changes in metabolic parameters, intestinal permeability, and gastrointestinal symptoms in individuals who have undergone bariatric surgery (Laparoscopic Sleeve Gastrectomy - LSG) for obesity treatment.\n\nObesity is a chronic disease associated with serious health complications including type 2 diabetes, hypertension, cardiovascular disease, and metabolic disorders. Bariatric surgery is currently the most effective treatment method for morbid obesity. However, monitoring patients after surgery in terms of metabolic health, gut permeability, and gastrointestinal symptoms is crucial for long-term success.\n\nIn this study, 40 volunteers (aged 19-50) who have undergone LSG surgery within the last month will be followed for 6 months. At the beginning of the study and 6 months later, the following will be assessed:\n\n* Metabolic parameters: fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) cholesterol, and insulin levels\n* Intestinal permeability markers: zonulin, secretory immunoglobulin A (IgA), and lipopolysaccharide (LPS) levels\n* Gastrointestinal symptoms: assessed using the Gastrointestinal Symptom Rating Scale (GSRS)\n* Anthropometric measurements: body weight, height, waist and hip circumference, BMI\n* Nutritional intake: 3-day dietary records\n\nThe study will be conducted at Bursa Yıldırım Doruk Hospital, General Surgery Clinic. Results will contribute to understanding the relationship between bariatric surgery and gut health, potentially helping to prevent postoperative complications.",[26,472,502,503,504],"Intestinal Permeability","Gastrointestinal Symptoms","Metabolic Syndrome",[506,507,508,509,510,511,512,513],"Laparoscopic Sleeve Gastrectomy","Zonulin","Secretory IgA","Lipopolysaccharide","GSRS","Body Weight Management","Gut microbiota","Postoperative Metabolic Parameters","2026-06-08",{"date":516,"type":37},"2026-06-11",{"date":518,"type":22},"2026-07-01",{"date":520,"type":22},"2027-02-01",{"name":522,"class":44},"Toros University"]